Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b

NaPi2b-PL2202 - ADC Therapeutics

https://www.abstractsonline.com/pp8/#!/20272/presentation/1531

E. Horsley 1; A. Jabeen 1; N. Veillard 1; K. Havenith 1; N. Janghra 1; P. Alves 1; C. Oblette 1; I. Kirby 1; P. W. Hogg 1; F. Zammarchi 2; L. de Haan 1; P. v. Berkel1

Mar 6, 2024